SCHEMBL21906930

SCHEMBL21906930

Bc1c(B)c(B)c2c(-c3ccc4oc5ccccc5c4c3)c3c(B)c(B)c(B)c(B)c3c(-c3ccccc3)c2c1B

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.44
NPC1 O15118 3/20 0.44
HPGD P15428 3/20 0.44
RAB9A P51151 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
KDM4E B2RXH2 2/20 0.44
MEN1 O00255 2/20 0.44
ALDH1A1 P00352 2/20 0.44
KMT2A Q03164 2/20 0.44
PLA2G2A P14555 4/20 0.41
PLA2G4A P47712 4/20 0.41
AHR P35869 2/20 0.40
PLA2G10 O15496 1/20 0.40
CA1 P00915 2/20 0.39
CA2 P00918 2/20 0.39
LMNA P02545 1/20 0.38
GABRP O00591 1/20 0.37
GABRD O14764 1/20 0.37
CA12 O43570 1/20 0.37
TNKS O95271 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21906986 0.98 PLA2G2A (0.43) MAPTNPC1HPGDRAB9ASMN1; SMN2
SCHEMBL25007208 0.98 PLA2G2A (0.43) MAPTNPC1HPGDRAB9ASMN1; SMN2
SCHEMBL21907986 0.96 PLA2G2A (0.46) MAPTNPC1HPGDRAB9ASMN1; SMN2
SCHEMBL21907324 0.95 PLA2G2A (0.47) MAPTNPC1HPGDRAB9ASMN1; SMN2
SCHEMBL24479342 0.95 PLA2G2A (0.47) MAPTNPC1HPGDRAB9ASMN1; SMN2
SCHEMBL24479799 0.95 PLA2G2A (0.47) MAPTNPC1HPGDRAB9ASMN1; SMN2
SCHEMBL24766989 0.94 PLA2G2A (0.45) MAPTNPC1HPGDRAB9ASMN1; SMN2
SCHEMBL21906991 0.93 PLA2G2A (0.40) MAPTNPC1HPGDRAB9ASMN1; SMN2
SCHEMBL24822862 0.93 PLA2G2A (0.42) MAPTNPC1HPGDRAB9ASMN1; SMN2
SCHEMBL21906987 0.93 PLA2G2A (0.46) MAPTNPC1HPGDRAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230011996-A1 ORGANIC ELECTROLUMINESCENCE DEVICE AND ELECTRONIC APPARATUS PROVIDED WITH THE SAME IDEMITSU KOSAN CO., LTD. (JP) 2023-01-12 US disclosed
US-20220411437-A1 NOVEL COMPOUND, ORGANIC ELECTROLUMINESCENCE DEVICE AND ELECTRONIC APPARATUS IDEMITSU KOSAN CO.,LTD. (JP) 2022-12-29 US disclosed
US-20220169656-A1 NOVEL COMPOUND, ORGANIC ELECTROLUMINESCENCE DEVICE AND ELECTRONIC APPARATUS IDEMITSU KOSAN CO., LTD. (JP) 2022-06-02 US disclosed
US-20210376255-A1 ORGANIC LIGHT EMITTING DEVICE LG DISPLAY CO., LTD. (KR) 2021-12-02 US disclosed
US-10804474-B2 Organic electroluminescence device and electronic apparatus provided with the same IDEMITSU KOSAN CO., LTD. (JP) 2020-10-13 US disclosed
US-10763444-B2 Organic electroluminescence device and electronic apparatus provided with the same IDEMITSU KOSAN CO., LTD. (JP) 2020-09-01 US disclosed
US-20200111974-A1 ORGANIC ELECTROLUMINESCENCE DEVICE AND ELECTRONIC APPARATUS PROVIDED WITH THE SAME IDEMITSU KOSAN CO., LTD. (JP) 2020-04-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220411437-A1 NOVEL COMPOUND, ORGANIC ELECTROLUMINESCENCE DEVICE AND ELECTRONIC APPARATUS RPS19, TERT, PIEZO1 MAPT 3856/4885NPC1 2643/4885HPGD 3729/4885
US-20230011996-A1 ORGANIC ELECTROLUMINESCENCE DEVICE AND ELECTRONIC APPARATUS PROVIDED WITH THE SAME RER1, RPS19, ESR1 MAPT 4227/4885NPC1 2777/4885HPGD 3501/4885
US-20220169656-A1 NOVEL COMPOUND, ORGANIC ELECTROLUMINESCENCE DEVICE AND ELECTRONIC APPARATUS RPS19, TERT, PIEZO1 MAPT 3856/4885NPC1 2643/4885HPGD 3729/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.